menu
    • menu
    [{"orgOrder":0,"company":"St. Jude Children's Research Hospital","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"||Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase II","graph3":"St. Jude Children's Research Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"St. Jude Children's Research Hospital \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"St. Jude Children's Research Hospital \/ AbbVie Inc"},{"orgOrder":0,"company":"St. Jude Children's Research Hospital","sponsor":"Pfizer Inc | Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"||Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase II","graph3":"St. Jude Children's Research Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"St. Jude Children's Research Hospital \/ Pfizer Inc | Amgen Inc","highestDevelopmentStatusID":"8","companyTruncated":"St. Jude Children's Research Hospital \/ Pfizer Inc | Amgen Inc"},{"orgOrder":0,"company":"Tanja Andrea Gruber","sponsor":"Pediatric Oncology ETIC | Amgen Inc | Lucile Packard Foundation for Children's Health | Kura Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"||Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tanja Andrea Gruber","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Tanja Andrea Gruber \/ Pediatric Oncology ETIC | Amgen Inc | Lucile Packard Foundation for Children's Health | Kura Oncology","highestDevelopmentStatusID":"7","companyTruncated":"Tanja Andrea Gruber \/ Pediatric Oncology ETIC | Amgen Inc | Lucile Packard Foundation for Children's Health | Kura Oncology"},{"orgOrder":0,"company":"Children's Oncology Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Mercaptopurine","moa":"||Amidophosphoribosyltransferase | DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Children's Oncology Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Children's Oncology Group \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Children's Oncology Group \/ Inapplicable"},{"orgOrder":0,"company":"Children's Cancer Group, China","sponsor":"Shanghai Children's Medical Center | Beijing Children's Hospital | Children's Hospital of Scow University | West China Second University Hospital | Nanjing Children's Hospital | Qilu Hospital of Shandong University | Tianjin Medical University Cancer Inst","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Prednisone","moa":"||Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Children's Cancer Group, China","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Cancer Group, China \/ Shanghai Children's Medical Center | Beijing Children's Hospital | Children's Hospital of Scow University | West China Second University Hospital | Nanjing Children's Hospital | Qilu Hospital of Shandong University | Tianjin Medical University Cancer Inst","highestDevelopmentStatusID":"10","companyTruncated":"Children's Cancer Group, China \/ Shanghai Children's Medical Center | Beijing Children's Hospital | Children's Hospital of Scow University | West China Second University Hospital | Nanjing Children's Hospital | Qilu Hospital of Shandong University | Tianjin Medical University Cancer Inst"},{"orgOrder":0,"company":"University of Michigan Rogel Cancer Center","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dasatinib","moa":"||Tyrosine-protein kinase ABL | Bcr\/Abl fusion protein | Platelet-derived growth factor receptor beta | Ephrin type-A receptor 2 | SRC | Stem cell growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"University of Michigan Rogel Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Michigan Rogel Cancer Center \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"University of Michigan Rogel Cancer Center \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Cleveland Clinic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Melatonin","moa":"||MTN1A receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Cleveland Clinic","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cleveland Clinic \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Cleveland Clinic \/ Inapplicable"},{"orgOrder":0,"company":"Anabio R&D","sponsor":"Vietstar Biomedical Research | Thai Binh University of Medicine and Pharmacy","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"Bacillus Subtilis","moa":"||Bacteria microbiome","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Anabio R&D","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anabio R&D \/ Vietstar Biomedical Research | Thai Binh University of Medicine and Pharmacy","highestDevelopmentStatusID":"1","companyTruncated":"Anabio R&D \/ Vietstar Biomedical Research | Thai Binh University of Medicine and Pharmacy"}]

    Find Clinical Drug Pipeline Developments & Deals for 6 Mercaptopurine Monohydrate

    Menu

    6 Mercaptopurine Monohydrate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Children's Oncology Group

                            Country arrow
                            EPSC
                            Not Confirmed

                            Children's Oncology Group

                            Country arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mercaptopurine,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of Different Programs to Help ALL Patients With Taking Maintenance Medicine at Home

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 15, 2024

                            Lead Product(s) : Mercaptopurine,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Anabio R&D

                            Country arrow
                            EPSC
                            Not Confirmed

                            Anabio R&D

                            Country arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bacillus Subtilis,Bacillus Clausii,Sulfasalazine,Prednisone,Azathioprine,Mercaptopurine,Metronidazole

                            Therapeutic Area : Gastroenterology

                            Study Phase : Undisclosed

                            Sponsor : Vietstar Biomedical Research | Thai Binh University of Medicine and Pharmacy

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy of LiveSpo COLON as a Supportive Treatment for Inflammatory Bowel Disease (IBD)

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            October 15, 2024

                            Lead Product(s) : Bacillus Subtilis,Bacillus Clausii,Sulfasalazine,Prednisone,Azathioprine,Mercaptopurine,Metronidazole

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Undisclosed

                            Sponsor : Vietstar Biomedical Research | Thai Binh University of Medicine and Pharmacy

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            St. Jude Children's Research Hospital

                            Country arrow
                            EPSC
                            Not Confirmed

                            St. Jude Children's Research Hospital

                            Country arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dexamethasone,Vincristine Sulfate,Inotuzumab,Blinatumomab,Dasatinib,Cyclophosphamide,Cytarabine,Methotrexate,Mercaptopurine,Calaspargase,Daunorubicin,Thioguanine

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Pfizer Inc | Amgen Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Steroid

                            Upfront Cash : Inapplicable

                            August 01, 2024

                            Lead Product(s) : Dexamethasone,Vincristine Sulfate,Inotuzumab,Blinatumomab,Dasatinib,Cyclophosphamide,Cytarabine,Methotrexate,Mercaptopurine,Calaspargase,Daunorubicin,Thioguanine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Pfizer Inc | Amgen Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            St. Jude Children's Research Hospital

                            Country arrow
                            EPSC
                            Not Confirmed

                            05

                            Tanja Andrea Gruber

                            Country arrow
                            EPSC
                            Not Confirmed

                            Tanja Andrea Gruber

                            Country arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dexamethasone,Mitoxantrone,Peg L asparaginase,Bortezomib,Vorinostat,Mercaptopurine,Methotrexate,Blinatumomab,Ziftomenib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Pediatric Oncology ETIC | Amgen Inc | Lucile Packard Foundation for Children's Health | Kura Oncology

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Steroid

                            Upfront Cash : Inapplicable

                            May 08, 2023

                            Lead Product(s) : Dexamethasone,Mitoxantrone,Peg L asparaginase,Bortezomib,Vorinostat,Mercaptopurine,Methotrexate,Blinatumomab,Ziftomenib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Pediatric Oncology ETIC | Amgen Inc | Lucile Packard Foundation for Children's Health | Kura Oncology

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Children's Cancer Group, China

                            Country arrow
                            EPSC
                            Not Confirmed

                            Children's Cancer Group, China

                            Country arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Prednisone,Vincristine Sulfate,Pegylated-Asparaginase,Bortezomib,Cytarabine,Cyclophosphamide,Daunorubicin,Mercaptopurine,Methotrexate,Dexamethasone,Doxorubicin Hydrochloride,Vindesine Sulfate,Etoposide,Ifosfamide

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Shanghai Children's Medical Center | Beijing Children's Hospital | Children's Hospital of Scow University | West China Second University Hospital | Nanjing Children's Hospital | Qilu Hospital of Shandong University | Tianjin Medical University Cancer Inst

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children with Newly Diagnosed T-cell Lymphobl...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Steroid

                            Upfront Cash : Inapplicable

                            January 12, 2023

                            Lead Product(s) : Prednisone,Vincristine Sulfate,Pegylated-Asparaginase,Bortezomib,Cytarabine,Cyclophosphamide,Daunorubicin,Mercaptopurine,Methotrexate,Dexamethasone,Doxorubicin Hydrochloride,Vindesine Sulfate,Etoposide,Ifosfamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Shanghai Children's Medical Center | Beijing Children's Hospital | Children's Hospital of Scow University | West China Second University Hospital | Nanjing Children's Hospital | Qilu Hospital of Shandong University | Tianjin Medical University Cancer Inst

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            University of Michigan Rogel Cancer Center

                            Country arrow
                            EPSC
                            Not Confirmed

                            08

                            Cleveland Clinic

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Cleveland Clinic

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Melatonin,Mercaptopurine,Sirolimus

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Melatonin? Stem Cells? Researchers Step Up With Unconventional Approaches To COVID-19

                            Details : Cleveland Clinic compared COVID-19 with the coronavirus that caused the SARS outbreak of 2003 using a technique called “network proximity analysis” to identify combinations of existing drugs.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 16, 2020

                            Lead Product(s) : Melatonin,Mercaptopurine,Sirolimus

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Children's Oncology Group

                            Country arrow
                            EPSC
                            Not Confirmed

                            10

                            University of Chicago

                            Country arrow
                            EPSC
                            Not Confirmed